GlaxoSmithKline's diabetes drug Avandia to be restricted on US market
As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled type 2 diabetes agent Avandia (rosiglitazone), the drug will be removed from the US market in November and will only be available through a special program for those patients who need to continue with the therapy.
The controversy about Avandia’s safety (it has been linked with increased risk of heart attacks) has seen sales of the drug plunge from a peak of $3 billion to just $680 million last year, and less than $60 million in the first quarter of this year (The Pharma Letters passim). GSK has also made a massive $3.5 billion provision for legal liability cases connected with the drug.
Safety announcement
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze